Perspective
Our work in Perspective
-
Government And Commercial Insurer Payment Rates to Hospitals: A Commentary on Priselac
Paul Ginsburg discusses how for decades, stakeholders have argued about whether competition or regulation should be the approach to constrain health care spending. By having chosen neither, he argues, our nation now finds itself with a much larger challenge. The magnitude of our health care affordability problem cries out for pursuing both competition and regulation.
Categorized in -
We Can Find Cancers with a Simple Blood Test
As a cancer researcher and a health economist, we’ve seen up close through our lab and consulting work the revolution contained in a blood draw. But cancer detection blood tests aren’t built into annual physicals like standard blood tests, and so far they aren’t covered by insurance.
Categorized in -
Podcast: Jack Chapel on Health Trends in a Shrinking Middle Class
Health Affairs Editor-in-Chief Alan Weil interviews Jack Chapel, a PhD candidate in economics at the USC Dornsife College of Letters, Arts and Sciences, about a new study examining the worsening health and economic trends for Americans with modest resources nearing retirement.
Categorized in -
Responses to Request for Information Regarding Medical Payment Products
Schaeffer experts submitted a comment letter responding to a recent request for information (RFI) regarding medical payment products.
Categorized in -
Comments to CMS on Proposed Guidance for Coverage with Evidence Development
Eleven Schaeffer fellows cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations on the proposed Coverage with Evidence Development Guidance.
Categorized in -
Beware of the Government’s Healthcare ‘Truth’ Peddlers
The Biden administration’s efforts to regulate, either explicitly or through indirect government coercion, what it deems to be “misinformation” in healthcare not only runs counter to our shared values but can be dangerous to our health.
Categorized in -
Responses to Congressional Request for Information about Cannabidiol from US Congress
Schaeffer experts submitted a comment letter responding to a recent request for information (RFI) related to cannabidiol.
Categorized in -
Blame Capitalism? Why Hundreds of Decades-Old Yet Vital Drugs Are Nearly Impossible to Find
The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs.
Categorized in -
Centers for Disease Control and Prevention Guideline for Prescribing Opioids, 2022—Need for Integrating Dosing Benchmarks with Shared Decision-Making
A fully individualized, unstructured decision-making process
will not be adequate to protect patients receiving long-term opioid
therapy.Categorized in -
Congress Can Eradicate Hepatitis C and Reduce the Deficit at the Same Time
The initiative comes with a $12.3 billion price tag — and over 10 years, the savings in health care costs will reach $18.1 billion.
Categorized in